Pyuria in patients treated with indinavir is associated with renal dysfunction

Clinical Nephrology

Volumn 54, Issue 4, 2000, Pages 261-270

  Sarcletti, M ^a   Petter, A ^a   Romani, N ^a   Lhotta, K ^a   Konig, P ^a   Maier, H ^a   Zangerle, R ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Indinavir; Interstitial disease; Pyuria; Renal dysfunction; Tubulo

Indexed keywords

CREATININE; INDINAVIR;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; CRYSTALLURIA; DRUG WITHDRAWAL; DYSURIA; FEMALE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY COLIC; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; NEPHROTOXICITY; PYURIA; RETROSPECTIVE STUDY; RISK FACTOR; URINE PH;

ADULT; CREATININE; FEMALE; HIV PROTEASE INHIBITORS; HUMAN; INDINAVIR; KIDNEY CALCULI; KIDNEY DISEASES; MALE; MIDDLE AGE; PYURIA; TIME FACTORS;

EID: 0033778315     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection
2. Indinavir nephrolithiasis in warm climates
3. Metabolites of L 735,524 a potent HIV-1 protease inhibitor in human urine
4. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans
5. Acute renal failure due to indinavir crystalluria and nephrolithiasis: Report of two cases
6. Changes in renal function associated with indinavir
7. Urolithiasis associated with the protease inhibitor indinavir
8. Urinary stones in HIV-1-positive patients treated with indinavir
9. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
10. Light microscopy of indinavir urinary crystals
11. Protease inhibitor-induced urolithiasis
12. Indinavir-induced nephropathy
13. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
14. A controlled trial of two nucleoside analogues plus indinavir in persons with human immuno-deficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
15. Renal atrophy associated with long-term treatment with indinavir
16. Urolithiasis and the protease inhibitor indinavir
17. Indinavir urolithiasis: An emerging cause of renal colic in patients with human immunodeficiency virus
18. Crystalluria and urinary tract abnormalities associated with indinavir
19. Indinavir and interstitial nephritis - In response
20. pH-dependent oral absorption of I-735,524, a potent HIV protease inhibitor, in rats and dogs
21. Sex-dependent pharmacokinetics of indinavir: In vivo and in vitro evidence
22. Acute interstial nephritis secondary to the administration of indinavir
23. Indinavir crystal deposits associated with tubulointerstial nephropathy
24. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type I disease treated with protease inhibitors
25. Indinavir nephropathy in an AIDS patient with renal insufficiency
26. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed
27. Management of indinavir associated nephrolithiasis
28. Crystalluria and nephrolithiasis during therapy with the protease inhibitor indinavir
29. Protease inhibitor therapy in children with perinatally acquired HIV infection
30. Indinavir and in-terstitial nephritis
31. Urolithiasis associated with protease inhibitors
32. Protease inhibitors and urolithiasis
33. Indinavir nephropathy
34. Single-dose pharmacokinetics of indinavir and the effect of food